Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04904510 · ClinicalTrials.gov registry record
Evaluation of the INDICAID™ COVID-19 Rapid Antigen Test
A clinical trial of COVID-19, sponsored by University of California, Los Angeles.
- Completed
- Registry status
- 297
- Enrollment target
- 1
- Study location
NCT04904510: Completed study of COVID-19, sponsored by University of California, Los Angeles.
NCT04904510 is a study of COVID-19 that has completed, run by University of California, Los Angeles. The registered enrollment target is 297 participants, below the 38,464-participant average among 298 other COVID-19 trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04904510, a study of COVID-19, has completed, sponsored by University of California, Los Angeles.
- COMPLETED
- Registry status
- 297 participants
- Enrollment target
- 1
- Study location
Study Summary
The INDICAID™ Rapid Antigen Test was used in real-world outbreak testing. The antigen test was used together with PCR testing. This study was designed to evaluate whether the addition of a rapid antigen test decreased time to results in a real-world setting.
Primary Outcome
The concordance with the INDICAID COVID-19 Rapid Antigen Test with an EUA PCR test
Conditions Studied
Interventions
- DIAGNOSTIC_TEST INDICAID™ COVID-19 Rapid Antigen Test
Study Locations (1)
California
- CityHealth Urgent Care Oakland - Oakland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 297 participants |
| Start Date | 2020-11-20 |
| Est. Completion | 2021-03-09 |
What the finished NCT04904510 record still lists
NCT04904510 is an observational study that tracks outcomes without assigning an intervention. The registered 297 participants enrollment target is mid-sized for trials with a published cap, below the 38,464-participant average among 298 other COVID-19 trials with a reported enrollment target (99% lower).
The record links to 1 condition, with COVID-19 appearing as the primary indexed condition, and to 1 intervention - of which INDICAID™ COVID-19 Rapid Antigen Test is the first listed.
NCT04904510 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT04904510 about?
NCT04904510 is a clinical study titled "Evaluation of the INDICAID™ COVID-19 Rapid Antigen Test". The INDICAID™ Rapid Antigen Test was used in real-world outbreak testing. The antigen test was used together with PCR testing. This study was designed to evaluate whether the addition of a rapid antigen test decreased time to results in a real-world setting.
What is the current status of trial NCT04904510?
This trial is currently completed. The enrollment target is 297 participants. The study started on 2020-11-20. Estimated completion is 2021-03-09.
What conditions does trial NCT04904510 study?
This clinical trial studies the following conditions: COVID-19.
What interventions are being tested in trial NCT04904510?
The interventions under investigation include: INDICAID™ COVID-19 Rapid Antigen Test (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04904510?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04904510 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for COVID-19
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04904510's enrollment target sits among peer trials
297 143rd of 298 higher than 156 of 298 other COVID-19 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other COVID-19 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
CArdiac REhabilitation for Building Exertional heArt Rate for Chronotropic Incompetence in Long COVID-19
RECRUITING · NA
-
Arginine Replacement Therapy in COVID-19
RECRUITING · Phase 2
-
A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children
RECRUITING · Phase 2
-
Cardiac Magnetic Resonance Tissue Characterization in COVID-19 Survivors
RECRUITING
-
COVID-19 Health Adjustments in Nutrition, General Wellness, and Exercise
RECRUITING
-
The Impact of COVID-19 on Maternal and Neonatal Outcomes
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06309160 · 297 participants · NA
COMPASS Across Settings (CAST) for Improving Transition Outcomes for Students With ASD
- NCT06375811 · 297 participants · Phase 3
Pre-IVF Treatment With a GnRH Antagonist in Women With endometriosis_temp
- NCT07222215 · 297 participants · Phase 2
PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)
- NCT06305624 · 298 participants · NA
Implementation of Mobile-based Programs for Alcohol Cessation in Treatment of Alcohol-associated Liver Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI